SVRA News and Press, Savara Inc. From 09/05/23

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25 th Annual Global Investment Conference on September 12, 2023 at 3:30pm ET/12:30pm PT. A live webcast o...

2023-08-10 17:20:13 ET Savara press release ( NASDAQ: SVRA ): Q2 GAAP EPS of -$0.07 beats by $0.01 . $105M in Cash and Cash Equivalents at the End of 2Q 2023 For further details see: Savara GAAP EPS of -$0.07 beats by $0.01

Fully Enrolled Pivotal Phase 3 IMPALA-2 Trial Remains On-Track to Report Top Line Data by End of 2Q 2024 — 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Prote...

2023-07-16 11:50:23 ET Summary Today, we circle back on a small development firm called Savara for the first time in over two years. Its primary drug candidate is being developed for a rare affliction that has no approved therapies and has a pivotal readout coming up in the second...

2023-07-13 08:27:10 ET Jiuzi ( NASDAQ: JZXN ) +73% . Snail ( SNAL ) +43% . 60 Degrees Pharmaceuticals ( SXTP ) +35% . Applied DNA Sciences ( APDN ) +8% acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT( TM ) Platform to Su...

2023-07-13 07:08:33 ET Savara ( NASDAQ: SVRA ) prices an underwritten offering of 21M common shares at $3.00 per share and 5.66M pre-funded warrants to purchase common stock at a price of $2.999 per pre-funded warrant for total gross proceeds of approximately $80 million. All ...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 21,000,000 shares of its common stock at a price of $3.00 per share and, in lieu of common stock to certain investors that so c...

2023-06-26 16:30:03 ET Savara ( SVRA ) said Monday that it has been added to the U.S. broad-market Russell 3000 Index at the conclusion of the Russell indexes annual reconstitution. Press Release . For further details see: Savara joins Russell ...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has been added to the U.S. broad-market Russell 3000 ® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. mark...

Target Enrollment was 160 Patients, IMPALA-2 Enrolled 164 Patients Company Remains On-Track to Report Top Line Data by End of 2Q 2024 Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that enrol...